Lundbeck Expands Geographical Rights for Circadin

H. Lundbeck A/S and Neurim Pharmaceuticals Ltd. have announced that Lundbeck has obtained expanded exclusive rights to commercialize Circadin in Asia, Latin America and other major markets such as Australia and Turkey. Following regulatory filing and approval Lundbeck expects to market Circadin in the first markets outside of Europe in 2009.

Under the terms of the agreement Neurim will receive an upfront payment and a share of revenue. The upfront payment will be deducted from the share of revenue in the first three years of commercialization. Neurim is responsible for manufacturing.

Circadin, a novel sleep aid, was approved by the European Commission in June 2007 indicated as monotherapy for the short-term treatment of primary insomnia characterized by poor quality of sleep in patients aged 55 and above. The approval was based on clinical trials that show positive effects on sleep induction, sleep quality, and most importantly, day-time functioning and quality of life. The trials also show that there are no signs of development of dependency.

"Circadin is a unique treatment of poor sleep with a new mechanism that differs from all other approved medicines. With this new agreement we will now be able to offer this valuable alternative to traditional sedative hypnotics in a number of markets worldwide to the benefit of the many patients suffering from sleep disorder problems," says Executive Vice President Stig Løkke Pedersen, head of Commercial Operations.

For further information please contact:

Jacob Tolstrup

Director

Tel: +45 36 43 30 79

Email: jtl@lundbeck.com